(Q51872961)

English

Impact of depression on treatment effectiveness and gains maintenance in social phobia: a naturalistic study of cognitive behavior group therapy.

scientific article published in January 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

15 April 2018

http://europepmc.org/abstract/MED/19170088

Impact of depression on treatment effectiveness and gains maintenance in social phobia: a naturalistic study of cognitive behavior group therapy. (English)

1 reference

Europe PubMed Central

15 April 2018

http://europepmc.org/abstract/MED/19170088

group psychotherapy

1 reference

based on heuristic

inferred from title

Abraham Weizman

4

object named as

Abraham Weizman

1 reference

Europe PubMed Central

15 April 2018

http://europepmc.org/abstract/MED/19170088

author name string

Sofi Marom

1

1 reference

Europe PubMed Central

15 April 2018

http://europepmc.org/abstract/MED/19170088

Eva Gilboa-Schechtman

2

1 reference

Europe PubMed Central

15 April 2018

http://europepmc.org/abstract/MED/19170088

Idan M Aderka

3

1 reference

Europe PubMed Central

15 April 2018

http://europepmc.org/abstract/MED/19170088

Haggai Hermesh

5

1 reference

Europe PubMed Central

15 April 2018

http://europepmc.org/abstract/MED/19170088

publication date

1 January 2009

1 reference

Europe PubMed Central

15 April 2018

http://europepmc.org/abstract/MED/19170088

Depression and Anxiety

1 reference

Europe PubMed Central

15 April 2018

http://europepmc.org/abstract/MED/19170088

26

1 reference

Europe PubMed Central

15 April 2018

http://europepmc.org/abstract/MED/19170088

289-300

1 reference

Europe PubMed Central

15 April 2018

http://europepmc.org/abstract/MED/19170088

3

1 reference

Europe PubMed Central

15 April 2018

http://europepmc.org/abstract/MED/19170088

Social phobia subtypes in the National Comorbidity Survey.

1 reference

https://api.crossref.org/works/10.1002%2FDA.20390

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FDA.20390

21 January 2018

Assessing psychiatric impairment in primary care with the Sheehan Disability Scale

1 reference

https://api.crossref.org/works/10.1002%2FDA.20390

21 January 2018

Social phobia: overview of community surveys.

1 reference

https://api.crossref.org/works/10.1002%2FDA.20390

7 January 2021

based on heuristic

inferred from DOI database lookup

Considering comorbidity in social phobia

1 reference

https://api.crossref.org/works/10.1002%2FDA.20390

7 January 2021

based on heuristic

inferred from DOI database lookup

Antecedents of the risk of recovery from DSM-III-R social phobia.

1 reference

https://api.crossref.org/works/10.1002%2FDA.20390

7 January 2021

based on heuristic

inferred from DOI database lookup

Evidence-Based Pharmacotherapy of Social Anxiety Disorder

1 reference

https://api.crossref.org/works/10.1002%2FDA.20390

7 January 2021

based on heuristic

inferred from DOI database lookup

Cognitive-behavioral therapy for social anxiety disorder

1 reference

https://api.crossref.org/works/10.1002%2FDA.20390

7 January 2021

based on heuristic

inferred from DOI database lookup

Recent Advances in the Treatment of Social Phobia: Introduction to the Special Issue

1 reference

https://api.crossref.org/works/10.1002%2FDA.20390

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomised controlled general practice trial of sertraline, exposure therapy and combined treatment in generalised social phobia

1 reference

https://api.crossref.org/works/10.1002%2FDA.20390

7 January 2021

based on heuristic

inferred from DOI database lookup

Fluoxetine, comprehensive cognitive behavioral therapy, and placebo in generalized social phobia

1 reference

https://api.crossref.org/works/10.1002%2FDA.20390

7 January 2021

based on heuristic

inferred from DOI database lookup

Do empirically supported treatments generalize to private practice? A benchmark study of a cognitive-behavioural group treatment programme for social phobia

1 reference

https://api.crossref.org/works/10.1002%2FDA.20390

7 January 2021

based on heuristic

inferred from DOI database lookup

Effectiveness of an empirically supported treatment for social phobia in the field.

1 reference

https://api.crossref.org/works/10.1002%2FDA.20390

7 January 2021

based on heuristic

inferred from DOI database lookup

Predictors of response to cognitive-behavioral group therapy for social phobia

1 reference

https://api.crossref.org/works/10.1002%2FDA.20390

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical features affecting treatment outcome in social phobia

1 reference

https://api.crossref.org/works/10.1002%2FDA.20390

7 January 2021

based on heuristic

inferred from DOI database lookup

Comorbid anxiety and mood disorders among persons with social anxiety disorder

1 reference

https://api.crossref.org/works/10.1002%2FDA.20390

7 January 2021

based on heuristic

inferred from DOI database lookup

Impact of depressive symptoms on the treatment of generalized social anxiety disorder

1 reference

https://api.crossref.org/works/10.1002%2FDA.20390

7 January 2021

based on heuristic

inferred from DOI database lookup

Prediction of treatment outcome in social phobia: a cross-validation

1 reference

https://api.crossref.org/works/10.1002%2FDA.20390

7 January 2021

based on heuristic

inferred from DOI database lookup

The Liebowitz social anxiety scale as a self-report instrument: a preliminary psychometric analysis

1 reference

https://api.crossref.org/works/10.1002%2FDA.20390

7 January 2021

based on heuristic

inferred from DOI database lookup

The Liebowitz Social Anxiety Scale: a comparison of the psychometric properties of self-report and clinician-administered formats.

1 reference

https://api.crossref.org/works/10.1002%2FDA.20390

7 January 2021

based on heuristic

inferred from DOI database lookup

Psychometric properties and three proposed subscales of a self-report version of the Liebowitz Social Anxiety Scale translated into Hebrew

1 reference

https://api.crossref.org/works/10.1002%2FDA.20390

7 January 2021

based on heuristic

inferred from DOI database lookup

Psychometric properties of disability measures among patients with social anxiety disorder.

1 reference

https://api.crossref.org/works/10.1002%2FDA.20390

7 January 2021

based on heuristic

inferred from DOI database lookup

A New Depression Scale Designed to be Sensitive to Change

1 reference

https://api.crossref.org/works/10.1002%2FDA.20390

7 January 2021

based on heuristic

inferred from DOI database lookup

The Montgomery-Asberg Depression Scale: reliability and validity.

1 reference

https://api.crossref.org/works/10.1002%2FDA.20390

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment outcome for chronic PTSD among female assault victims with borderline personality characteristics: a preliminary examination.

1 reference

https://api.crossref.org/works/10.1002%2FDA.20390

7 January 2021

based on heuristic

inferred from DOI database lookup

Social phobia symptoms: prevalence, sociodemographic correlates, and overlap with specific phobia symptoms

1 reference

https://api.crossref.org/works/10.1002%2FDA.20390

7 January 2021

based on heuristic

inferred from DOI database lookup

Anxious and depressive disorders and their comorbidity: effect on central nervous system noradrenergic function

1 reference

https://api.crossref.org/works/10.1002%2FDA.20390

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized, double-blind, placebo-controlled study of citalopram in adolescents with major depressive disorder.

1 reference

https://api.crossref.org/works/10.1002%2FDA.20390

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical significance: A statistical approach to defining meaningful change in psychotherapy research

1 reference

https://api.crossref.org/works/10.1002%2FDA.20390

7 January 2021

based on heuristic

inferred from DOI database lookup

A simple and valid tool distinguished efficacy from effectiveness studies

1 reference

https://api.crossref.org/works/10.1002%2FDA.20390

7 January 2021

based on heuristic

inferred from DOI database lookup

Cognitive therapy versus fluoxetine in generalized social phobia: a randomized placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FDA.20390

7 January 2021

based on heuristic

inferred from DOI database lookup

Psychometric properties of the Liebowitz Social Anxiety Scale.

1 reference

https://api.crossref.org/works/10.1002%2FDA.20390

7 January 2021

based on heuristic

inferred from DOI database lookup

Cognitive therapy versus exposure and applied relaxation in social phobia: A randomized controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FDA.20390

7 January 2021

based on heuristic

inferred from DOI database lookup

Exposure therapy and sertraline in social phobia: I-year follow-up of a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FDA.20390

7 January 2021

based on heuristic

inferred from DOI database lookup

Mediation of changes in anxiety and depression during treatment of social phobia

1 reference

https://api.crossref.org/works/10.1002%2FDA.20390

7 January 2021

based on heuristic

inferred from DOI database lookup

Psychological and pharmacological treatments of social phobia: a meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2FDA.20390

7 January 2021

based on heuristic

inferred from DOI database lookup

Cognitive-Behavioral and Pharmacological Treatment for Social Phobia: A Meta-Analysis

1 reference

https://api.crossref.org/works/10.1002%2FDA.20390

7 January 2021

based on heuristic

inferred from DOI database lookup

Cognitive therapy for social phobia: individual versus group treatment.

1 reference

https://api.crossref.org/works/10.1002%2FDA.20390

7 January 2021

based on heuristic

inferred from DOI database lookup

Intensive cognitive-behavioral group treatment (CBGT) of social phobia: A randomized controlled study

1 reference

https://api.crossref.org/works/10.1002%2FDA.20390

7 January 2021

based on heuristic

inferred from DOI database lookup

Are Specific and Generalized Social Phobias Qualitatively Distinct?

1 reference

https://api.crossref.org/works/10.1002%2FDA.20390

7 January 2021

based on heuristic

inferred from DOI database lookup

The efficacy of videotape feedback for enhancing the effects of exposure-based treatment for social anxiety disorder: a controlled investigation.

1 reference

https://api.crossref.org/works/10.1002%2FDA.20390

7 January 2021

based on heuristic

inferred from DOI database lookup

Social skills training augments the effectiveness of cognitive behavioral group therapy for social anxiety disorder

1 reference

https://api.crossref.org/works/10.1002%2FDA.20390

7 January 2021

based on heuristic

inferred from DOI database lookup

Pre-existing antidepressants and the outcome of group cognitive behaviour therapy for social phobia

1 reference

https://api.crossref.org/works/10.1002%2FDA.20390

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment attrition during group therapy for social phobia

1 reference

https://api.crossref.org/works/10.1002%2FDA.20390

7 January 2021

based on heuristic

inferred from DOI database lookup

The evidence-based pharmacological treatment of social anxiety disorder

1 reference

https://api.crossref.org/works/10.1002%2FDA.20390

7 January 2021

based on heuristic

inferred from DOI database lookup

A 24-week randomized, double-blind, placebo-controlled study of escitalopram for the prevention of generalized social anxiety disorder.

1 reference

https://api.crossref.org/works/10.1002%2FDA.20390

7 January 2021

based on heuristic

inferred from DOI database lookup

Reliability of DSM-IV anxiety and mood disorders: implications for the classification of emotional disorders

1 reference

https://api.crossref.org/works/10.1002%2FDA.20390

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/DA.20390

1 reference

Europe PubMed Central

15 April 2018

http://europepmc.org/abstract/MED/19170088

1 reference

Europe PubMed Central

15 April 2018

http://europepmc.org/abstract/MED/19170088

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51872961&oldid=1832293092"